Rigel Pharmaceuticals director Kamil Ali-Jackson sold 2,500 shares of common stock at $35.00 per share in an open-market transaction. After the sale, she directly holds 10,125 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025 and, according to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than for investment purposes.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey received a fully vested employee stock option tied to a performance goal. The award covers 7,394 shares of common stock at an exercise price of $22.49 per share. The performance metric was confirmed as met on June 17, 2026, triggering vesting, and the option expires on January 29, 2035. This is a compensation-related grant, not an open-market share purchase or sale.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a performance-based stock option grant that became fully vested on June 17, 2026. The award covers 31,700 shares of common stock under an employee stock option, with an exercise price of $22.49 per share and an expiration date of January 29, 2035. The filing shows this as a compensation-related acquisition, not an open-market buy or sale, and lists 31,700 derivative shares held following the transaction.
Rigel Pharmaceuticals EVP and Chief Medical Officer Lisa Rojkjaer reported the vesting of previously granted performance-based stock options. On June 17, 2026, performance metrics were determined to be met for options covering 9,375 shares at an exercise price of $14.90 and 7,394 shares at $22.49.
Both option grants became fully vested on June 17, 2026. The 9,375-share grant was originally made on March 27, 2024 and adjusted for a one-for-ten reverse stock split effective June 27, 2024, while the 7,394-share grant was made on January 29, 2025.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported the acquisition of an employee stock option covering 7,394 shares of common stock. The option was originally granted on January 29, 2025 with an exercise price of $22.49 per share.
The award carried a performance-based vesting condition and was not reportable until that metric was satisfied. On June 17, 2026, the company determined the performance metric had been met, and the option became fully vested, leaving Schorno with 7,394 option shares following the transaction.
RIGEL PHARMACEUTICALS EVP and Chief Commercial Officer David A. Santos reported a performance-based stock option award covering 7,394 shares of common stock. The option has an exercise price of $22.49 per share and an expiration date of January 29, 2035.
The award was originally granted on January 29, 2025 with a performance-based vesting condition, and it became fully vested on June 17, 2026 when the company determined that the performance metric had been met.
Kamil Ali-Jackson reports a sale of 2,500 shares of common stock. The filing shows 2,500 shares were sold on 05/26/2026 for $72,925.00, with Fidelity Brokerage Services LLC listed as the broker. The securities were reported as vested restricted stock with a vesting date of 05/21/2024.
Rigel Pharmaceuticals, Inc. completed a major licensing transaction, making its License Agreement with Arvinas, Inc., Arvinas affiliates and Pfizer Inc. effective for VEPPANU™ (vepdegestrant). The deal grants Rigel exclusive, global rights to develop, manufacture and commercialize VEPPANU and related products worldwide.
Following early termination of the Hart-Scott-Rodino antitrust waiting period and satisfaction of closing conditions, Rigel closed the transaction and paid the licensors a one-time upfront payment of $70.0 million.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno exercised stock options and settled related taxes in shares. On June 1, 2026, he exercised options for 2,181 shares of common stock at $12.70 per share and 1,200 shares at $18.70 per share. To cover tax obligations, 928 shares of common stock were disposed of at a value of $29.86 per share, a tax-withholding transaction rather than an open-market sale. Following these transactions, he directly held 78,790 shares of Rigel common stock. The filing also notes all share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.
RIGEL PHARMACEUTICALS INC executive David A. Santos, EVP and Chief Commercial Officer, reported a small share disposition related to taxes. On this date, 874 shares of common stock were delivered at $29.86 per share to cover tax obligations. After this tax-withholding event, Santos directly holds 61,996 shares of common stock, indicating that his overall ownership position remains largely unchanged.